Loading...
XKRX234080
Market cap116mUSD
Jan 08, Last price  
10,990.00KRW
1D
0.37%
1Q
-0.72%
Jan 2017
-19.63%
IPO
-35.92%
Name

JW Life Science Corp

Chart & Performance

D1W1MN
XKRX:234080 chart
P/E
6.05
P/S
0.82
EPS
1,817.55
Div Yield, %
4.55%
Shrs. gr., 5y
-0.45%
Rev. gr., 5y
5.91%
Revenues
206.86b
+9.49%
84,121,031,19089,090,518,89088,614,186,790111,121,369,220125,950,120,610132,290,404,970143,599,849,110155,230,052,160170,220,779,250183,521,045,080169,816,950,010188,931,165,240206,860,371,797
Net income
28.14b
+88.11%
2,658,535,4003,467,947,0101,632,618,9309,356,571,44012,864,212,71015,161,608,51016,782,714,41015,820,963,90021,938,439,04017,300,052,45012,913,619,14014,961,266,84028,143,966,400
CFO
37.57b
+165.94%
14,765,055,03017,554,452,04010,795,451,51013,844,732,67025,896,778,71016,081,152,66022,050,000,57036,129,922,79024,275,563,95046,754,700,49030,165,045,65014,128,750,70037,574,248,440
Dividend
Dec 27, 2023500 KRW/sh

Profile

JW Lifescience Corporation engages in the development, production, and sale of infusion solutions in South Korea and internationally. It offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin, South Korea.
URL
https://www.jw-lifescience.co.kr/
IPO date
Oct 27, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
206,860,372
9.49%
188,931,165
11.26%
Cost of revenue
169,330,980
155,308,943
Unusual Expense (Income)
NOPBT
37,529,392
33,622,222
NOPBT Margin
18.14%
17.80%
Operating Taxes
5,564,302
5,820,578
Tax Rate
14.83%
17.31%
NOPAT
31,965,089
27,801,644
Net income
28,143,966
88.11%
14,961,267
15.86%
Dividends
(7,742,277)
(7,742,277)
Dividend yield
3.89%
4.12%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
46,098,144
37,147,858
Long-term debt
306,275
30,218,595
Deferred revenue
Other long-term liabilities
141,950
508,067
Net debt
4,393,726
58,818,974
Cash flow
Cash from operating activities
37,574,248
14,128,751
CAPEX
(8,153,142)
(8,293,469)
Cash from investing activities
8,036,512
(28,247,198)
Cash from financing activities
(29,308,312)
13,115,140
FCF
38,119,074
20,447,462
Balance
Cash
28,347,661
28,872,694
Long term investments
13,663,033
(20,325,215)
Excess cash
31,667,675
Stockholders' equity
137,806,616
134,531,104
Invested Capital
174,180,223
203,085,383
ROIC
16.95%
14.97%
ROCE
18.07%
16.39%
EV
Common stock shares outstanding
15,485
15,485
Price
12,870.00
5.93%
12,150.00
-12.27%
Market cap
199,286,210
5.93%
188,137,331
-12.81%
EV
203,679,936
246,956,305
EBITDA
53,060,095
48,578,313
EV/EBITDA
3.84
5.08
Interest
2,693,103
3,091,935
Interest/NOPBT
7.18%
9.20%